News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Fighting Cancer: Duke Researchers Make Progress Against Tumors


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.localtechwire.com/article.cfm?u=6300

Posted on: 12/08/2003

Fighting Cancer: Duke Researchers Make Progress Against Tumors

By Allan Maurer, LocalTechWire

RESEARCH TRIANGLE - Researchers at Duke Comprehensive Cancer Center have shown that four new experimental drugs slow the growth of deadly brain tumors in animals.

Jeremy Rich, M.D., assistant professor of medicine in the Brain Tumor Center at Duke, tells Local Tech Wire the results are not only expected to hold true in humans as well, they also have "broad applicability to other cancer types."

Three of the drugs plug small pockets inside cancer cells to stop a molecule called ATP from docking. This in turn prevents the cancer cells from starting the murderous chain of events leading to uncontrolled growth.

One drug blocks angiogenesis, the process by which tumor cells grow new blood vessels. This much-touted approach to attacking cancer gained notoriety several years ago when a New York Times reporter claimed the method might result in a "cure for cancer" that failed to materialize in the short time predicted.

But cancer researchers today aren't talking about a "cure," says Rich. Instead, he says new drugs such as those undergoing testing at Duke may let doctors treat cancer as a chronic, manageable disease.

One of the new drugs, which helps prevent tumors from evading the immune system, may make some other current treatments more effective, Rich says.

Two of the drugs work better together than either alone and will begin testing in humans within a year. "Some are supposed to go into clinical trials in the next couple of month," he adds.

The new drugs also herald the dawn of a new age of personalized medicine. "In the future, the idea is that we take a person's cancer back into the lab and then say we're going to make cocktail X-91," says Rich. "All roads may lead to Rome, but every road may be different."

Several drug companies, including Genentech, Astra Zeneca, Glaxo, and Abarta support the Duke cancer research. Rich says, "We work with the companies. They own the drugs. We are also working on generating our own drugs."




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740